The Therapeutic Pipeline for Pseudomonas aeruginosa Infections
Due to its high levels of intrinsic and acquired antibiotic resistance, the opportunistic pathogen Pseudomonas aeruginosa has been designated by the World Health Organization as a bacteria of critical priority for the development of new therapeutic strategies. In a recent review in ACS Infectious Diseases, Dr. Lori Burrows summarizes the novel ways in which researchers and companies are trying to kill this bacteria, given its incredible versatility, robust efflux mechanisms that limit drug penetration, and ability to form antimicrobial-tolerant biofilms, amongst other factors. Burrow’s goes further to highlight that although these strategies show great potential for the prevention and treatment of P. aeruginosa infections, successful mitigation requires improved drug-resistant strain surveillance and stewardship programs, and continued investments in early-stage drug discovery efforts by governments and industry.
Read the full review in ACS Infectious Diseases.
NewsRelated News
News Listing
April 26, 2024